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lymphocytes develop within the thymus, where they
are positively selected for self-restriction and purged of
cells exhibiting strong reactivity to self-antigens presented
within this microenvironment. Mature lymphocytes then
enter the peripheral lymphoid pool, where they recirculate
between the various secondary lymphoid organs, including
the spleen and the lymph nodes that drain peripheral tissues
(1). It is almost exclusively within these lymphoid tissues
that T lymphocytes first encounter antigen. The rapid re-
circulation of the total lymphocyte repertoire within the
relatively confined secondary lymphoid compartment, in
combination with the effective movement of antigens from
peripheral sites to draining lymph nodes, permits highly ef-
ficient surveillance for infection throughout the whole or-
ganism. Thus, the secondary lymphoid organs effectively
bring together the key players required for immunity; no-
tably the T cells, their target antigen, and, importantly, the
APCs. It is the APCs that simultaneously provide a crucial
scaffold for effective recognition of extralymphoid (periph-
eral) tissue–derived antigen and, potentially, directly partic-
ipate in the movement of antigen from peripheral sites of
expression to the central locations where effective T cell
activation takes place. In this commentary, we will focus
on the trafficking and presentation of peripherally derived
antigens within the secondary lymphoid compartment, and
discuss emerging evidence suggesting that this presentation
is not only responsible for effective T cell priming, but may
also function in the induction of T cell tolerance to self-anti-
gens expressed exclusively by peripheral tissues.
 
Cross-tolerance: Tolerance Induced by Cellular Antigens Indi-
rectly Presented by Bone Marrow–derived APCs.
 
Evidence that
cellular antigens can be transferred and indirectly presented
by professional APCs can be traced to early experiments
examining the MHC-restriction of responses to minor his-
tocompatibility antigens (2–5). For example, Bevan primed
 
(BALB/c 
 
3 
 
BALB/B)F1 mice (H-2
 
d
 
 
 
3 
 
H-2
 
b
 
) with cells
from C57BL/10 (B10) mice, which shared H-2
 
b
 
 MHC
molecules but differed in their expression of B10 minors
(4). As expected, H-2
 
b
 
–restricted CTLs specific for B10
minors were induced by this immunization, but, unexpect-
edly, so were H-2
 
d
 
–restricted CTLs. Concluding that in
order to induce an H-2
 
d
 
–restricted response, minor anti-
gens must have been transferred to APCs of host origin,
Bevan coined the term “cross-priming”, referring to the
CTL priming associated with the capture and presentation
of cell-derived antigens by host APCs. We have used this
definition as the basis of the term “cross-presentation”,
which signifies the presentation event itself. By extension,
tolerance that results from such cross-presentation has been
called “cross-tolerance”. Traditionally, these terms have re-
ferred to access of exogenous antigens (primarily cell-derived
antigens) to the class I pathway, whereas indirect presenta-
tion has referred to the presentation of cell-derived antigens
via the class II pathway. For simplicity, here we will use the
term cross-presentation to encompass both class I– and class
II–restricted pathways.
 
Cross-presentation Permits Recognition of Peripheral Antigens
by Lymph Node T Cells.
 
These early cross-priming exper-
iments, which primarily focused on class I–restricted CTL
responses, led to the suggestion that cross-presentation rep-
resented a mechanism whereby T cells could be primed to
antigens expressed in peripheral sites, such as those resulting
from tissue-tropic virus infection (6, 7). Furthermore, the
subsequent realization that the cytosolic-based MHC class
I–restricted antigen presentation pathway normally ex-
cluded presentation of exogenous antigen (8), strongly im-
plied that either the form of the antigen, or the APCs
themselves, possessed some special properties enabling ac-
cess to the class I pathway (6, 9).
Although the identity of a specialized cross-presenting
APC, explored below, remains contentious, the formal
demonstration of cross-presentation of peripheral tissue–
derived antigen has been achieved in recent years. This
demonstration required the generation of transgenic ani-
mals expressing antigens exclusively within defined periph-
eral tissues, under the control of tissue-specific promoters.
Lo et al. used bone marrow chimeras to show that hemag-
glutinin expressed by islet 
 
b
 
 cells could be cross-presented
within the pancreas to CD4
 
1
 
 T cells by a bone marrow–
derived APC (10).
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Class I–restricted cross-presentation of peripheral tissue
antigens was formally demonstrated using transgenic mice
expressing ovalbumin (OVA) in the pancreas and kidney
(11). When OVA-specific CD8
 
1
 
 T cells were transferred
into these OVA-expressing mice, they proliferated specifi-
cally in those nodes that drained sites of OVA expression,
i.e., the pancreatic and renal lymph nodes. By manipulating
the MHC haplotype of the bone marrow compartment, it
was possible to show that the cell responsible for OVA pre-
sentation was derived from the bone marrow. Thus, under
normal conditions, a specialized APC was able to constitu-
tively capture OVA from the OVA-expressing tissues and
present it to CD8
 
1
 
 T cells in the draining lymph nodes.
 
Cross-tolerance as a Consequence of Bone Marrow–derived
APC Presentation of Peripheral Antigen.
 
Although the ex-
periments of Kurts et al. showed that CD8
 
1
 
 T cells were
activated and proliferated in lymph nodes draining the sites
of peripheral antigen expression (11), this did not represent
effective T cell priming. Long-term examination of the
survival of these CD8
 
1
 
 T cells revealed their gradual dele-
tion from the peripheral T cell pool (12). Such deletion ap-
peared to be mediated by a mechanism related to activa-
tion-induced cell death, since it was preceded by an active
proliferative response (12) and was recently shown to be
dependent on signaling through CD95 (fas, Apo-1; 12a).
These studies revealed that cross-presentation of self-
antigens by a bone marrow–derived APC provided a mecha-
nism  for induction of peripheral tolerance, at least for
CD8
 
1
 
 T cells. A somewhat similar mechanism of bone
marrow–derived, APC-mediated CD8
 
1
 
 T cell cross-toler-
ance had been observed previously within the thymus by
von Boehmer and Hafen (13).
Like CD8
 
1
 
 T cells, CD4
 
1
 
 T cells specific for a model
autoantigen, SV40 T antigen (14, 15), have been reported
to be activated in the draining lymph nodes of those organs
expressing this protein. In this case also, proliferation was
followed by deletion, although some remaining cells exhib-
ited properties of anergy (15). Adler et al. now extend these
findings in mice expressing hemagglutinin in various pa-
renchymal cells, by showing that CD4
 
1
 
 T cell tolerance is
mediated by cross-presentation of this antigen on a bone
marrow–derived APC (16). Here, tolerance is induced
only when the responding autoreactive CD4
 
1
 
 T cell popu-
lation is provided with bone marrow–derived cells express-
ing the correct MHC haplotype to present hemagglutinin.
In this case, the tolerance induced is more consistent with
anergy, although it is difficult to rule out contributions by a
deletional mechanism.
In support of a role for professional APCs in tolerance
induction, CD4
 
1
 
 T cell tolerance to hen egg lysozyme ex-
pressed as a model self-antigen was fas-dependent and pre-
ceded by proliferation (17), indicating that the cell respon-
sible for tolerance induction had the capacity to activate
naive T cells, a property supposedly linked to professional
APCs. Furthermore, CTLA-4 signaling by B7 (expressed
primarily by B cells and professional APCs) was shown to
be involved in the induction of peripheral tolerance to a
soluble exogenous antigen capable of inducing T cell an-
ergy (18).
Taken together, there is compelling evidence that in or-
der to maintain self-tolerance a specialized APC is capable
of capturing tissue antigens, transporting them to the lym-
phoid compartment, i.e., the draining lymph nodes, and
presenting them to both naive CD4
 
1
 
 and CD8
 
1
 
 T cells. It
should be emphasized that it is yet to be established whether
the APC traffics with antigen or is resident in the lymphoid
compartment and merely captures antigens draining to this
site. Whatever the case, this APC appears to be capable of pro-
cessing exogenous antigens into the class I and class II path-
ways. Moreover, although the conventional view is that
“professional” APCs are constitutively involved in productive
T cell activation (priming), the combined data clearly show
that such APCs can also tolerize T cells under certain cir-
cumstances.
 
Ignorance Versus Tolerance?
 
The above data argue for the
existence of a “professional” APC that constitutively in-
duces tolerance to antigens expressed in extralymphoid tis-
sues. This is consistent with numerous reports of tolerance
to peripheral antigens (12, 14–16, 19), but how then can
we explain other reports of immunological ignorance (20–
25), where naive CD4
 
1
 
 or CD8
 
1
 
 T cells neither respond
to nor are tolerized by peripheral tissue antigens? Perhaps
the answer to this apparent contradiction comes from the
efficiency of transport and presentation of parenchymal an-
tigens by the APCs responsible for tolerance induction. In
studies using transgenic mice expressing different levels of
OVA in the pancreas, we have recently found that antigen
concentration is critical in determining whether such anti-
gens are cross-presented in the draining lymph nodes.
 
1
 
 In
brief, although OVA expressed at high levels was cross-pre-
sented in these lymph nodes, and may induce tolerance, a
lower level of OVA expression was ignored by naive T
cells. However, this low dose could still sensitize islet 
 
b
 
cells for recognition and destruction by activated CTLs,
mimicking the ignored antigens reported by others (20,
21). Thus, the level of antigen expression appears to deter-
mine whether an antigen induces cross-tolerance or is ig-
nored by naive T cells.
 
What Is the APC That Mediates Cross-tolerance?
 
Whether
the same APC is responsible for inducing both the CD4
 
1
 
 T
cell tolerance to hemagglutinin reported by Adler et al. (16)
and the CD8
 
1
 
 T cell tolerance to OVA seen in our own
model (12) is unclear. More recently, we showed that pro-
vision of CD4
 
1
 
 T cell help, in the form of large numbers of
transgenic CD4
 
1
 
 T cells specific for OVA, severely impairs
the deletion of autoreactive CD8
 
1
 
 T cells in mice express-
ing OVA in the pancreas and kidneys (26). Since CD4
 
1
 
help for CTL induction must be mediated through the same
APC as seen by the CD8
 
1
 
 cell (27–29), this finding is consis-
tent with the idea that the same APC presents both class
I– and class II–restricted determinants. However, it should be
 
1
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emphasized that class II–restricted presentation of exogenous
antigens is a normal property of all class II–bearing bone mar-
row–derived populations, including dendritic cells (DCs),
macrophages, and B cells, so more than one cell type may
contribute to this process.
It is interesting to note that deletion of both CD4
 
1
 
 (14,
15) and CD8
 
1
 
 T cells (12) is preceded by a period of pro-
liferation, suggesting that the APC responsible for tolerance
induction must be capable of activating T cells into prolif-
erative cycles. This supports the idea that the tolerogenic
APC is of the professional class, expressing the costimula-
tory molecules necessary to push a naive T cell into cell cy-
cle. It is perhaps not that unusual to find that antigens can
induce tolerance when presented by bone marrow–derived
cells, since several antigens including H-Y, superantigens,
and soluble peptide appear to be tolerogenic when pre-
sented generally by this compartment (30–33). What is im-
portant is the implication that the tolerogenic APC is a cell
capable of trafficking from peripheral tissues to draining
lymph nodes and there initiating the proliferation of naive
T cells. Even more importantly for CD8
 
1
 
 T cell tolerance,
this APC must be capable of capturing exogenous antigens
and cross-presenting them in the class I pathway. Various
cell types have been shown to have the capacity to cross-
present exogenous antigens in vitro, including myeloid-derived
DCs (34, 35), macrophages (36, 37), and B cells (38). If
trafficking from peripheral tissues to draining lymph nodes
is essential, then it is unlikely to be a B cell, which unless
activated would remain in the secondary lymphoid com-
partment. Macrophages may migrate from tissues to drain-
ing lymph nodes, but usually require exposure to pathogen
products or lymphokines for expression of class II mole-
cules. These cells are therefore not likely to present cap-
tured tissue antigens to CD4
 
1
 
 T cells under normal cir-
cumstances.
On the other hand, the myeloid DC constitutively ex-
presses class II molecules and may traffic from peripheral
tissues to draining lymph nodes, making this cell a potential
candidate. In support of this view, myeloid DCs grown
from human peripheral blood were shown to present exog-
enous antigen via the class I presentation pathway (35). In-
terestingly, this study demonstrated a preference for antigen
derived from cells undergoing virally induced apoptosis,
consistent with the original notion that this presentation
pathway, at least for class I, represents a mechanism for pe-
ripheral immune surveillance against viral infection (6). In
our own studies using whole animals, cross-presentation of
islet antigens to CD8
 
1
 
 T cells was dramatically enhanced
when islet 
 
b
 
 cells were killed by activated CTL.
 
1
 
 These re-
sults are consistent with the idea that apoptosis facilitates
cross-presentation in vivo and suggest that this may play a
role in tolerance and/or immunity to peripherally ex-
pressed antigens.
Another cell type that may fit the profile of the cross-tol-
erance APC is the recently described lymphoid DC (39). It
is capable of activating both CD4 (40) and CD8 (41) cells
in vitro, and has been speculated to have an immunoregu-
latory role (40). Interestingly, these lymphoid DCs have
now been shown to occupy T cell areas of the spleen and
lymph nodes, and to express high levels of self-antigens
(42), raising the possibility of a role in the maintenance of
self-tolerance. Preliminary findings from our laboratory in-
dicate that fas signaling contributes to the deletion of
CD8
 
1
 
 T cells by cross-tolerance, leading to the conclusion
that CD95-ligand expression, perhaps by the APC, is cen-
tral to this form of peripheral tolerance (12a). Again, this
property correlates with the described attributes of the lym-
phoid DC (40).
 
What Determines Cross-tolerance Versus Cross-priming?
 
The
lymphoid DC is a good candidate for cross-tolerance in-
duction primarily because it is yet to be linked to a positive
immune response. However, another possibility is that the
traditional myeloid DC, or perhaps another member of the
macrophage/DC family (43), may be immunogenic under
some circumstances and tolerogenic under others. If this is
the case, then what determines the direction of the im-
mune response, and what is the difference between the sig-
nals that drive T cells into cycle in response to tolerogenic
stimulation with self-antigens versus immunogenic stimula-
tion with foreign antigens? As suggested by Matzinger,
“danger” signals from environmental pathogens may be the
key to positive immune responses (44). Because at least in
our model the tolerogenic response is preceded by prolifer-
ation, it would appear that the ability to induce prolifera-
tion of T cells is not the key to whether immunity is in-
duced, but rather it is a normal precursor to both
tolerogenic and immunogenic outcomes. In a number of
models (29, 45), CD4
 
1
 
 T cell “help” has been shown to be
important for induction of CTL immunity. Such “help”
even impairs the deletion of autoreactive CD8
 
1
 
 T cells in
the cross-tolerance to tissue antigens (26). Thus, as pro-
posed earlier (45), CD4
 
1
 
 T cell help may determine the di-
rection of responses by CD8
 
1
 
 CTL. But what determines
the direction of a CD4 response? This is probably one of
the outstanding questions at the moment, for if qualitative
expression of the costimulatory B7 molecules is not the de-
ciding factor, as argued by the fact that B cells express these
molecules but are tolerogenic to naive CD4
 
1
 
 T cells (46–
50), and by the observation that B7 may deliver signals
necessary for induction of peripheral tolerance (18), then
what molecular interactions provide the signals for immu-
nity versus tolerance? Perhaps there are other as yet unde-
fined costimulatory molecules that play a deciding role. Al-
ternatively, the level of either of the B7 molecules and their
competitive interactions with CD28 and CTLA4 may be
critical (51, 52). Whatever the case, there has to be a sig-
nal(s) that regulates professional APCs such that in a resting
state they are tolerogenic, and once activated they drive
immunity. At present, we favor the concept that these sig-
nals are derived from pathogens or, perhaps, tissue damage.
In conclusion, there is emerging evidence that APCs of
the “professional” class may be not only central to the traf-
ficking and presentation of foreign antigens for induction
of immunity, but they may also provide an important role 
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in the induction of cross-tolerance to peripheral tissue anti-
gens. Defining the specific APCs involved, the mechanism
of transport, and the molecular signals that determine
whether responses are immunogenic or tolerogenic will,
no doubt, provide us with a greater capacity to direct the
immune response to our own benefit.
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